摘要
目的:评价布地奈德鼻喷雾剂和氮卓斯汀鼻喷雾剂对季节性变应性鼻炎的疗效。方法:选取2018年2-9月本院收治的季节性变应性鼻炎患者156例,按治疗方法的不同分为A组(n=49)、B组(n=52)、C组(n=55)。A组单独使用布地奈德鼻喷雾剂治疗,B组单独使用氮卓斯汀喷雾剂治疗,C组采用布地奈德喷雾剂联合氮卓斯汀喷雾剂治疗,三组均持续用药4周。治疗2、4周后,对三组患者各鼻部症状评分(Multi-VAS)、总症状评分(Uni-VAS)和鼻结膜相关生活质量问卷(RQLQ)评分进行评价。结果:治疗2周后,鼻部各症状评分、总症状评分与治疗前比较,均有明显改善,且C组均低于A、B组,差异均有统计学意义(P<0.05),其中B组的鼻痒、流涕、喷嚏症状评分均低于A组,而A组鼻塞评分低于B组,差异均有统计学意义(P<0.05)。治疗4周后,C组鼻部各症状评分、总症状评分均低于A、B组,而A组又均低于B组,差异均有统计学意义(P<0.05)。治疗2周后,三组RQLQ评分均有下降,B组和C组在鼻部和眼部方面的评分下降最显著,其中C组RQLQ评分均低于A、B组,差异均有统计学意义(P<0.05)。治疗4周后,C组RQLQ评分均低于A、B组,A组RQLQ评分均低于B组,差异均有统计学意义(P<0.05)。三组不良反应发生率比较,差异无统计学意义(P>0.05)。结论:治疗季节性变应性鼻炎,短期内使用氮卓斯汀起效迅速,改善鼻部流涕症状明显;长期使用布地奈德疗效要好于氮卓斯汀,联合用药疗效要优于单独用药。
Objective: To evaluate the efficacy of Budesonide Nasal Spray and Azostine Nasal Spray on seasonal allergic rhinitis. Method: A total of 156 patients with seasonal allergic rhinitis admitted to our hospital from February to September 2018 were selected, group A(n=49), group B(n=51), and group C(n=55) according to different treatment methods. Group A was treated with Budesonide Nasal Spray alone, group B was treated with Azostine Nasal Spray alone, group C was treated with Budesonide Nasal Spray combined with Azostine Nasal Spray, all three groups were treated for 4 weeks. Three groups were continued medication for 4 weeks. The nasal symptom scores, Uni-VAS, rhinoconjunctivitis quality of life(RQLQ) were use to evaluated in 2 and 4 weeks after treatment. Result: After 2 weeks of treatment, the scores of nasal symptoms and total symptoms were significantly improved, and the scores of nasal symptoms in group C were lower than those in group A and group B, with statistically significant differences(P<0.05);the scores of nasal itching, runny nose and sneezing in group B were lower than those in group A, and the scores of nasal congestion in group A were lower than those in group B, with statistically significant differences(P<0.05). After 4 weeks of treatment, scores of nasal symptoms and total symptoms in group C were lower than those in group A and group B, while those in group A were lower than those in group B, with statistically significant differences(P<0.05). After 2 weeks of treatment, RQLQ scores of all three groups decreased, while those of group B and group C showed the most significant decrease in nasal and ocular areas, RQLQ scores of group C were lower than those of group A and group B, with statistically significant difference(P<0.05). After 4 weeks of treatment, RQLQ score of group C was lower than those of group A and group B, and RQLQ score of group A was lower than that of group B, with statistically significant differences(P<0.05). There was no significant difference in the incidence of adverse rea
作者
周晓琼
司马贞华
刘元珍
聂永芳
ZHOU Xiaoqiong;SIMA Zhenhua;LIU Yuanzhen;NIE Yongfang(Ji’an Hospital of Shanghai East Hospital,Ji’an 343000,China)
出处
《中国医学创新》
CAS
2019年第29期5-9,共5页
Medical Innovation of China
基金
吉安市科技计划项目[吉市科计字[2017]5号(68)]
